Cover Image
市場調查報告書

癌症的基因治療市場分析

Cancer Gene Therapy Market Analysis

出版商 KuicK Research 商品編碼 302591
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症的基因治療市場分析 Cancer Gene Therapy Market Analysis
出版日期: 2014年03月01日 內容資訊: 英文 300 Pages
簡介

基因治療市場從初期的研究階段,轉換為進行各種疾病治療用藥物臨床開發階段。現在是基因治療主要應用的癌症治療,佔臨床研究整體60%以上。這是由於癌症治療上有龐大的未滿足需求,以及該市場規模龐大。

本報告提供癌症的基因治療藥趨勢、基因治療對癌症治療的應用現狀、課題、基因治療市場法律規章方案、臨床實驗趨勢,以及參與企業的競爭環境彙整,為您概述為以下內容。

第1章 基因治療的簡介

  • 基因治療的歷史
  • 基因治療的載體

第2章 全球基因治療市場

  • 市場概要
  • 基因治療的新興趨勢

第3章 基因治療中癌症治療的重要性

第4章 基因治療對癌症治療的應用現況

  • 現在可利用的癌症治療
  • 癌症基因治療的方法
  • 癌症治療使用的基因治療
  • 遺傳基因插入癌症患者的方法

第5章 癌症的基因治療市場趨勢

  • 癌症基因治療的偏好參數
  • 對癌症患者的基因治療應用的相關問題
  • 癌症的基因治療臨床趨勢

第6章 法律規章方案

  • EU
  • 美國

第7章 各相、國家、標的適應症臨床實驗趨勢

  • 不明階段
  • 研究
  • 前臨床
  • 第1、2階段
  • 第二階段
  • 第三階段

第8章 已上市癌症的基因治療藥物

第9章 中止、中斷的開發平台

  • 沒有開發報告
  • 中止
  • 中斷

第10章 競爭環境

  • Advantagene
  • BioCancell
  • Celgene
  • Cell Genesys
  • Epeius Biotechnologies
  • GenVec
  • Introgen Therapeutics
  • MultiVir
  • ZIOPHARM Oncology
  • Shenzhen SiBiono GeneTech

圖表

目錄

The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.

A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines.

Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer.

Cancer Gene Therapy Report Highlights & Findings:

  • Cancer Gene Therapy Drugs in Pipeline: More Than 60
  • Highest Number of Drugs in Preclinical Stage: 37
  • Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100
  • Significance of Oncology Therapeutics in Gene Therapy
  • Current Applications of Gene Therapy to Cancer Treatment
  • Favorable Parameters for Cancer Gene Therapy
  • Issued Involved with Application of Gene Therapy in Cancer Patients
  • Regulatory Scenario for Gene Therapy Market
  • Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

Table of Contents

1. Introduction to Gene Therapy

  • 1.1. History of Gene Therapy
  • 1.2. Vectors of Gene Therapy

2. Global Gene Therapy Market

  • 2.1. Market Overview
  • 2.2. Emerging Trends in Gene Therapy

3. Significance of Cancer Therapeutics in Gene Therapy

4. Current Applications of Gene Therapy to Cancer Treatment

  • 4.1. Cancer Treatments Currently Available
  • 4.2. Approaches to Cancer Gene Therapy
  • 4.3. Gene Therapy Used in Cancer Treatment
  • 4.4. Methods of Inserting Genes into Cancer Patients

5. Cancer Gene Therapy Market Dynamics

  • 5.1. Favorable Parameters for Cancer Gene Therapy
  • 5.2. Issued Involved with Application of Gene Therapy in Cancer Patients
  • 5.3. Cancer Gene Therapy Clinical Insight

6. Regulatory Scenario for Gene Therapy Market

  • 6.1. EU
  • 6.2. US

7. Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

  • 7.1. Unknown Phase
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Phase I/II
  • 7.5. Phase II
  • 7.6. Phase III

8. Marketed Cancer Gene Therapy Drugs

9. Suspended & Discontinued Cancer Gene Therapy Drug Pipeline

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Suspended

10. Competitive Landscape

  • 10.1. Advantagene
  • 10.2. BioCancell
  • 10.3. Celgene
  • 10.4. Cell Genesys
  • 10.5. Epeius Biotechnologies
  • 10.6. GenVec
  • 10.7. Introgen Therapeutics
  • 10.8. MultiVir
  • 10.9. ZIOPHARM Oncology
  • 10.10. Shenzhen SiBiono GeneTech

List of Figures

  • Figure 3-1: Gene Therapy by Indication
  • Figure 5-1: Favorable Parameters for Cancer Gene Therapy
  • Figure 5-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
  • Figure 5-3: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number of Drugs), 2014
  • Figure 5-4: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
  • Figure 5-5: Suspended Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
  • Figure 5-6: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
  • Figure 5-7: Discontinued Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
  • Figure 5-8: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
  • Figure 5-9: No Development Reported Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Back to Top